000 01512cam  2200325za 4500
0019.858915
003CaOODSP
00520221107160124
007cr |||||||||||
008180711s2018    onc     o    f000 0 eng d
020 |a9780660271316
040 |aCaOODSP|beng
043 |an-cn---
0861 |aH13-9/17-2018E-PDF
24500|aGuidance document |h[electronic resource] : |buse of a foreign‐sourced reference product as a Canadian reference product.
24630|aUse of a foreign‐sourced reference product as a Canadian reference product
24617|aUse of a foreign‐sources reference product as a CRP
260 |aOttawa : |bHealth Canada, |c2018.
300 |a13 p.
500 |aIssued also in French under title: Ligne directrice : utilisation d'un produit de référence étranger comme produit de référence canadien.
500 |aCover title.
500 |a"Date adopted: 2017/11/24. Effective date: 2017/11/24. Administrative changes date: 2018/07/12."
500 |a"Publication date: July 2018."
500 |aIssued also in HTML format.
693 4|aDrug approval
7101 |aCanada. |bHealth Canada.
77508|tLigne directrice |w(CaOODSP)9.858918
85640|qPDF|s371 KB|uhttps://publications.gc.ca/collections/collection_2018/sc-hc/H13-9-17-2018-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/canadian-reference-product-guidance.html